Lilly's Foundayo pill reaches US pharmacies as early prescriptions trail oral Wegovy

Foundayo (orforglipron) is now on sale across the United States, Eli Lilly said on April 9, 2026, eight days after the FDA cleared the once-daily pill for weight loss ^[1][3]. Lilly began taking prescriptions on April 1, started shipping through its LillyDirect service on April 6, and added telehealth providers and retail pharmacies to the rollout on April 9 ^[1][3].

The first weeks of prescribing drew attention because they fell short of the launch of Novo Nordisk's oral Wegovy (semaglutide). Figures compiled by IQVIA and reported by Jefferies analysts counted 1,390 Foundayo prescriptions in its first week and 3,707 in the second ^[2]. The Wegovy pill, which arrived in January, posted more than 3,000 prescriptions in its first few days and 18,410 in its second week ^[2]. Analysts suggested the earlier launch benefited from pent-up demand for the first obesity treatment in pill form, after years in which GLP-1 weight-loss drugs required weekly injections ^[2]. Lilly's share price fell almost 4% after the numbers were reported ^[2].

Foundayo is approved for adults with obesity, and for some adults who are overweight and have a weight-related medical condition, alongside a reduced-calorie diet and increased physical activity ^[1]. It is an oral small-molecule GLP-1 that can be swallowed at any time of day, with no restrictions tied to food or water ^[1]. The oral Wegovy pill, by comparison, has to be taken first thing in the morning on an empty stomach, half an hour before eating or drinking ^[2].

In the ATTAIN-1 trial, a 72-week study of 3,127 adults with obesity or overweight plus at least one related condition, those on the top dose who stayed in treatment lost an average of 27.3 pounds, or 12.4% of body weight, against 2.2 pounds (0.9%) for placebo ^[1][3]. Counting everyone who enrolled whether or not they finished, the average was 25 pounds (11.1%) versus 5.3 pounds (2.1%) on placebo ^[1][3]. Lilly reported drops in waist circumference, non-HDL cholesterol, triglycerides and systolic blood pressure at every dose tested ^[1].

For people paying cash, the starting dose costs $149 a month through LillyDirect ^[1][3]. Those with commercial insurance that covers the drug may pay as little as $25 a month using a savings card ^[1][3]. Medicare Part D members who qualify may be able to obtain it for $50 a month starting July 1, 2026 ^[1][3]. Prices for higher doses under self-pay have not been disclosed. Lilly estimates that roughly half of Americans with job-based insurance have no coverage for obesity medicines ^[1].

The label says Foundayo should not be taken with other GLP-1 receptor agonist drugs, and its safety and effectiveness in children are unknown ^[1]. Warning material states the drug may cause thyroid tumors, including thyroid cancer, and lists pancreatitis, severe stomach problems, dehydration that can lead to kidney problems, low blood sugar, serious allergic reactions, gallbladder problems and vision changes in people with type 2 diabetes among possible serious risks ^[1]. Oral birth control pills may be less effective during treatment; the label says a provider may suggest a different contraceptive for 30 days after starting and after each dose increase ^[1]. One report on the launch says the label also restricts use with the cholesterol drug simvastatin ^[2].

Why it matters for patients

The arrival of a second obesity pill widens the choices available in a market that until this year meant weekly injections ^[2]. The practical difference patients are likely to notice first is scheduling: no waiting period before breakfast and no fasting window ^[1][2]. Cost depends heavily on insurance. The $149 price applies only to the lowest dose for people paying themselves, while the $25 figure requires a commercial plan that covers Foundayo plus the savings card, so out-of-pocket amounts will differ from person to person ^[1][3].

Foundayo is not meant to be stacked on top of another GLP-1 medicine, according to its label ^[1]. Its interaction with oral contraceptives is a consideration for anyone relying on that method of pregnancy prevention ^[1]. Early prescription counts reflect how quickly clinicians and patients took up the drug; they do not measure how much weight any individual loses ^[2].

What happens next

Lilly reports first-quarter results on April 30 and Novo Nordisk on May 6, which may offer a fuller read on demand for both pills ^[2]. Medicare Part D access at $50 a month is scheduled to start July 1, 2026 ^[1][3]. Lilly has filed orforglipron for weight management or type 2 diabetes in more than 40 countries and plans launches after approvals there ^[3]. The research firm Clarivate has projected $11.1 billion in obesity sales for the drug across major markets in 2031, plus $5.2 billion for diabetes ^[2].